Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$19.62 USD
+1.57 (8.70%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $19.72 +0.10 (0.51%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PE Ratio (TTM)
Arcturus Therapeutics Holdings Inc. has a trailing-twelve-months P/E of 14.42X compared to the Medical - Biomedical and Genetics industry's P/E of 22.20X.
Price to Earnings Ratio or P/E is price / earnings. It is the most commonly used metric for determining a company's value relative to its earnings. In this example, we are using the actual earnings (EPS) for the trailing twelve months (or TTM). A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its trailing twelve months earnings. In general, a lower number or multiple is usually considered better than a higher one.
ARCT 19.62 +1.57(8.70%)
Will ARCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates
Other News for ARCT
ARCT forms Bollinger Band Squeeze on September 18
Cathie Wood Invests $37M into Biotech Stocks, Trims Stake in KTOS, TEM, and ROKU Stocks
Shooting Star Candlestick appears for ARCT after 0.22% move
Cathie Wood Bets on AMD, Bullish, and Figma; Trims Tempus AI, Roku
Cathie Wood Bets on AMD, Figma, Bullish, and Biotech Plays, Trims Tempus AI, Roku